Retatrutide
Retatrutide is weight loss drug currently being tested to treat obesity and developed by Eli Lilly. Retatrutide (LY3437943) works differently to others by targeting three key hormone receptors: GLP-1, GIP, and glucagon. These hormones play a role in gut hormones, insulin production, and blood sugar control.
Early phase 2 trials show extremely encouraging results, with participants experiencing significant weight reduction. While Retatrutide is still under development, it represents a potential new approach to obesity management. Since it is not readily available for prescription, the cost of Retatrutide in the UK is still unknown.
| Brand | Medicine Strength | Size | Price |
|---|---|---|---|
| - | - | 1 | 0.00 |
It looks like you missed filling in questions from the last consultation.Click Here to submit your response.
Notify me once available
- No prescription required
- Online assessment
- No hidden fees
It is the prescribers duty to ensure that the medicine is being used safely and appropriately. please answer a few questions about yourself to help us process your request.
Customer Service Team
Confidentiality & Authenticity Assured
- Fully Regulated UK Pharmacy
- Authentic UK sourced medicines only.
- Trading for more than 10 years.
- Information Governance lead ensures all data is confidential
Need Help With Your Questionnaire?
Our customer service team is on hand Monday-Friday to help you with your queries.
Please call us on 08009788956 or
email us at: headoffice@pharmacyplanet.com
UK licenced
medication
100% Discretion
& Confidentiality
Cancel any
time
Retatrutide: A New Triple Threat Against Weight Loss
Imagine a drug that fights fat by talking to three different messengers in your body at the same time. That's the idea behind Retatrutide, a new medication being tested for obesity. Retatrutide , new weight loss injection acts as a triple agonist peptide targeting the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R), results in reducing the hunger and increasing metabolism simultaneously. This retatrutide injection is still in developmental phase and as soon as it becomes available, you can buy online in Pharmacy planet for the lowest price in the UK as effective weight loss treatment for obesity and diabetes.
Potential for More effective weighloss
Most weight-loss medications target one specific hormone or messenger. Retatrutide is new weight-loss medication developed by Eli Lilly which acts like a triple agent, influencing three hormonal receptors (GLP-1, GIP, and glucagon) that play a role in feeling full, blood sugar control, and gut hormones. By targeting multiple pathways, Retatrutide might lead to more significant weight loss compared to some existing medications.Retatrutide has demonstrated an average weight loss of 24% in clinical trials.
What is the Average Weight Loss on Retatrutide Injection?
In Phase 2 trial , participants on retatrutide experienced significant weight loss results. Anyone with BMI of 35 or higher saw a mean weight reduction of 26.5% with the 8-mg dose and 26.4% with the 12-mg dose, compared to 21.3% and 21.5% respectively for those with a lower BMI. Women tended to have a higher mean weight loss than men across both dose groups (28.5% and 26.6% vs. 19.8% and 21.9%). Additionally, after 48 weeks, the trial showed an average weight loss of 24%, with some participants losing more than 30% of their body weight on the highest dose of 12 mg.
Still Under Development
It's important to remember that Retatrutide is in the early stages of testing (like a practice round for a new game). More research is needed to confirm its long-term safety and effectiveness before it becomes widely available.
Can I buy Retatrutide online in the UK?
No, it is not currently available in the UK as it is still undergoing clinical trials and regulatory reviews before it can be approved for prescription.
When will Retatrutide pen be available in Stock in the UK?
Retatrutide has not yet been approved or released for purchase in the UK. As it is currently in Phase III of testing, and it may take a few years before it becomes available on the market. Therefore, it is not yet accessible for treating conditions such as obesity and type 2 diabetes.
Alternative weight loss treatment
As retatrutide is still under development, you can consider Wegovy , which is licensed for weight loss treatment in the UK
Retatrutide Benefits
Retatrutide works by activating GIP, GLP-1 and glucagon receptors which controls hunger and lead to weight loss. In the longer term, prolonged use can be effective in the treatment and management of obesity. Retatrutide is believed to help improve insulin sensitivity in patients with type 2 diabetes and helping to control blood glucose levels.
Early indications suggest that Retatrutide also appears to support the preservation of lean muscle mass during weight loss. Patients treated with earlier generations of weight loss medicines have complained of losing muscle mass along with fat during the weight loss experience.
Maintaining lean muscle mass is vital for metabolic function and maintaining results after a period of weight loss. Retatrutide, along with other GLP1 receptor agonist are also believed to have anti-inflammatory properties which could be beneficial for those dealing with chronic inflammation, offering a potential path to relief. It is important to remember however that currently these drugs have not been licensed for this purpose.
Retatrutide is also thought to help reduce cholesterol levels which can reduce the risk of cardiovascular issues.
Retatrutide vs semaglutide
Retatrutide is still in the development and testing phase, but it is likely to enter the market as a treatment for obesity and/or type 2 diabetes. In future, it is likely that both retatrutide and semaglutide will be used for managing the obesity or type 2 diabetes.
Semaglutide and retatrutide belong to the same family of medicines, their mechanisms of action differ slightly. Semaglutide works by copying the action of the natural hormone GLP-1 which helps the body to produce more insulin and slows down the speed at which your stomach empties (gastric emptying). These actions help to control the levels of sugar circulating in the blood, reduce appetite and subsequently cause weight loss.
Retatrutide, on the other hand, still targets the GLP-1 hormone pathway. However, it also works on two other hormone receptors GIP and GCG. Targeting these additional pathways is believed to make retatrutide an even more effective options for weight loss and blood sugar control.
Semaglutide is already widlely available in the UK in the brands Wegovy and Ozempic. While everyone knows the name Ozempic as a wonder weight loss drug, it is only approved in the UK for the treatment on type 2 diabetes. Wegovy is the brand of semaglutide that has been approved for use in weight management. It is injected once weekly and can only be prescribed under the guidance of a licensed healthcare professional.
Retatrutide is still in the testing phase and undergoing clinical trials to establish its safety and efficacy. So, retatrutide is still likely to take some time before coming to market here in the UK. Nevertheless, it shows enormous promise as an extremely effective medicine for weight loss and blood sugar control. Retatrutide’s full range of benefits, side effects are not yet fully understood but it displays huge potential to be at the vanguard of the next generation of weight loss drugs.
What is the recommended dosage chart for retatrutide?
As yet, there are no comprehensive dosing guidelines regarding retatrutide. Generally, medicines in this class are started at the lowest dose and gradually increased. This helps to minimise side effects and allows the body to adjust to the medicine before stepping up to higher, more efficacious strengths.
So far, based on the the published results of clinical trials, patients have been prescribed a variety of doses between 1 and 12mg. Patients on higher doses tended to have a high propensity for weight loss over the trial period. However, these patients also showed a higher likelihood of experiencing side effects from retatrutide.
So, it is likely that retatrutide will have a graduated dosing regimen, whereby the dose is increased incrementally at the beginning of treatment in order to minimise the adverse effects of the medicine. However, the specifics of the drug’s doses and dosing schedule will only be fully known when retatrutide receives its product license in the UK.
What are the potential interactions of retatrutide with other medications?
Like all medicines, retatrutide has the potential to interact with other drugs. These interactions may cause other drugs to be less or more effective, or they could minimise the effectiveness of retatrutide itself. Currently, the exact list of drugs that retatrutide may interact with is unknown and is currently being researched.
As with any new medicine, it is important to talk to your clinician about any other medicines you are taking before starting to take retatrutide.
Can I get Retatrutide over the counter in the UK?
No. Retatrutide is likely to enter the UK market as a prescription medication requiring consultation with a healthcare professional prior to its prescription. The clinician will examine your health and treatment goals with you and determine if retatrutide is suitable for you.
Be the first to know
Sign up to be the first to know when Retrutide becomes available by clicking the 'Notify me once available' button above and enter your email.
We'll keep you up to date with the latest developments concerning Retatrutide and let you know as soon as it becomes available in the UK.
Imagine a drug that fights fat by talking to three different messengers in your body at the same time. That's the idea behind Retatrutide, a new medication being tested for obesity. Retatrutide , new weight loss injection acts as a triple agonist peptide targeting the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R), results in reducing the hunger and increasing metabolism simultaneously. This retatrutide injection is still in developmental phase and as soon as it becomes available, you can buy online in Pharmacy planet for the lowest price in the UK as effective weight loss treatment for obesity and diabetes.
Most weight-loss medications target one specific hormone or messenger. Retatrutide is new weight-loss medication developed by Eli Lilly which acts like a triple agent, influencing three hormonal receptors (GLP-1, GIP, and glucagon) that play a role in feeling full, blood sugar control, and gut hormones. By targeting multiple pathways, Retatrutide might lead to more significant weight loss compared to some existing medications.Retatrutide has demonstrated an average weight loss of 24% in clinical trials.
In Phase 2 trial , participants on retatrutide experienced significant weight loss results. Anyone with BMI of 35 or higher saw a mean weight reduction of 26.5% with the 8-mg dose and 26.4% with the 12-mg dose, compared to 21.3% and 21.5% respectively for those with a lower BMI. Women tended to have a higher mean weight loss than men across both dose groups (28.5% and 26.6% vs. 19.8% and 21.9%). Additionally, after 48 weeks, the trial showed an average weight loss of 24%, with some participants losing more than 30% of their body weight on the highest dose of 12 mg.
Still Under Development
It's important to remember that Retatrutide is in the early stages of testing (like a practice round for a new game). More research is needed to confirm its long-term safety and effectiveness before it becomes widely available.
No, it is not currently available in the UK as it is still undergoing clinical trials and regulatory reviews before it can be approved for prescription.
Retatrutide has not yet been approved or released for purchase in the UK. As it is currently in Phase III of testing, and it may take a few years before it becomes available on the market. Therefore, it is not yet accessible for treating conditions such as obesity and type 2 diabetes.
As retatrutide is still under development, you can consider Wegovy , which is licensed for weight loss treatment in the UK
Retatrutide works by activating GIP, GLP-1 and glucagon receptors which controls hunger and lead to weight loss. In the longer term, prolonged use can be effective in the treatment and management of obesity. Retatrutide is believed to help improve insulin sensitivity in patients with type 2 diabetes and helping to control blood glucose levels.
Early indications suggest that Retatrutide also appears to support the preservation of lean muscle mass during weight loss. Patients treated with earlier generations of weight loss medicines have complained of losing muscle mass along with fat during the weight loss experience.
Maintaining lean muscle mass is vital for metabolic function and maintaining results after a period of weight loss. Retatrutide, along with other GLP1 receptor agonist are also believed to have anti-inflammatory properties which could be beneficial for those dealing with chronic inflammation, offering a potential path to relief. It is important to remember however that currently these drugs have not been licensed for this purpose.
Retatrutide is also thought to help reduce cholesterol levels which can reduce the risk of cardiovascular issues.
Retatrutide is still in the development and testing phase, but it is likely to enter the market as a treatment for obesity and/or type 2 diabetes. In future, it is likely that both retatrutide and semaglutide will be used for managing the obesity or type 2 diabetes.
Semaglutide and retatrutide belong to the same family of medicines, their mechanisms of action differ slightly. Semaglutide works by copying the action of the natural hormone GLP-1 which helps the body to produce more insulin and slows down the speed at which your stomach empties (gastric emptying). These actions help to control the levels of sugar circulating in the blood, reduce appetite and subsequently cause weight loss.
Retatrutide, on the other hand, still targets the GLP-1 hormone pathway. However, it also works on two other hormone receptors GIP and GCG. Targeting these additional pathways is believed to make retatrutide an even more effective options for weight loss and blood sugar control.
Semaglutide is already widlely available in the UK in the brands Wegovy and Ozempic. While everyone knows the name Ozempic as a wonder weight loss drug, it is only approved in the UK for the treatment on type 2 diabetes. Wegovy is the brand of semaglutide that has been approved for use in weight management. It is injected once weekly and can only be prescribed under the guidance of a licensed healthcare professional.
Retatrutide is still in the testing phase and undergoing clinical trials to establish its safety and efficacy. So, retatrutide is still likely to take some time before coming to market here in the UK. Nevertheless, it shows enormous promise as an extremely effective medicine for weight loss and blood sugar control. Retatrutide’s full range of benefits, side effects are not yet fully understood but it displays huge potential to be at the vanguard of the next generation of weight loss drugs.
As yet, there are no comprehensive dosing guidelines regarding retatrutide. Generally, medicines in this class are started at the lowest dose and gradually increased. This helps to minimise side effects and allows the body to adjust to the medicine before stepping up to higher, more efficacious strengths.
So far, based on the the published results of clinical trials, patients have been prescribed a variety of doses between 1 and 12mg. Patients on higher doses tended to have a high propensity for weight loss over the trial period. However, these patients also showed a higher likelihood of experiencing side effects from retatrutide.
So, it is likely that retatrutide will have a graduated dosing regimen, whereby the dose is increased incrementally at the beginning of treatment in order to minimise the adverse effects of the medicine. However, the specifics of the drug’s doses and dosing schedule will only be fully known when retatrutide receives its product license in the UK.
Like all medicines, retatrutide has the potential to interact with other drugs. These interactions may cause other drugs to be less or more effective, or they could minimise the effectiveness of retatrutide itself. Currently, the exact list of drugs that retatrutide may interact with is unknown and is currently being researched.
As with any new medicine, it is important to talk to your clinician about any other medicines you are taking before starting to take retatrutide.
No. Retatrutide is likely to enter the UK market as a prescription medication requiring consultation with a healthcare professional prior to its prescription. The clinician will examine your health and treatment goals with you and determine if retatrutide is suitable for you.
Sign up to be the first to know when Retrutide becomes available by clicking the 'Notify me once available' button above and enter your email.
We'll keep you up to date with the latest developments concerning Retatrutide and let you know as soon as it becomes available in the UK.
clinical consultation
Answer a few questions on your health and your fitness goals.
assessment
Our clinicians will review your clinical questionnaire to make sure treatment is right for you.
aboard!
Once approved, you will access our wealth of experience and resources curated by our team and begin your clinical weight loss journey.
No, Retatrutide is not the same as Semaglutide. While both medications are used to manage type 2 diabetes and work as GLP-1 receptor agonists, they have different mechanisms of action and clinical profiles.
| Retatrutide | Semaglutide | |
| Mechanism of Action | GLP-1 Agonist, GIP Agonist and Glucagon Agonist | GLP-1 Agonist |
| Primary Function |
It stimulates insulin release and curbs glucagon output Also affects gastric emptying and impacts the incretin system |
It stimulates insulin release and controls the glucagon output. It lowers the plasma glucose concentrations |
| Efficacy |
More effective in reducing fasting plasma glucose levels and LDL cholesterol Higher benefits for glycemic control |
More effective in reducing fasting plasma glucose levels. Cardio vascular benefitsr |
| Clinical Indications | Comprehensive metabolic health management |
Glycemic control Reduction in Cardiovascular-related risks |
Tirzepatide acts within two pathways, by mimicking the naturally occurring hormones GLP-1 and GIP, which are responsible for regulating the appetite and insulin secretion in response to meals. Meanwhile ,Retatrutide acts in three pathways i.e. GLP-1 Agonist, GIP and Glucagon Agonist which provides additional benefits of increased metabolic rate and suppressing appetite more effectively. This makes Retatrutide a comprehensive treatment option for managing both type 2 diabetes and obesity.
Though Retatrutide improves blood pressure and blood sugar levels, like other weight loss medications, Retatrutide can cause some side effects which may more likely be associated with gastrointestinal symptoms such as nausea, constipation, vomiting and diarrhoea. It remains uncertain if Retatrutide would cause the above side effects or severe health conditions as it is still in its testing phases.
The dose of Retatrutide has not been finalised since it is still in its development phase. Usually a dosage chart will be followed with every medication to ensure maximum potential of the dosage is attained and also to minimize the side effects. In Phase 2 of clinical trials , Participants were given following doses subcutaneously to understand the effects of the medication.
|
Group |
Dose |
Initial Dose |
Number of Participants |
Duration |
|
Retatrutide 1 mg |
1 mg | - |
1/10 of total participants |
48 weeks |
|
Retatrutide 4 mg (Group 1) |
4 mg | 2 mg |
1/10 of total participants |
48 weeks |
|
Retatrutide 4 mg (Group 2) |
4 mg |
4 mg |
1/10 of total participants |
48 weeks |
|
Retatrutide 8 mg (Group 1) |
8 mg |
2 mg |
1/10 of total participants |
48 weeks |
| Retatrutide 8 mg (Group 2) |
8 mg |
4 mg |
1/10 of total participants |
48 weeks |
|
Retatrutide 12 mg |
12 mg |
2 mg |
2/10 of total participants |
48 weeks |
|
Placebo |
- | - |
2/10 of total participants |
48 weeks |
Since Retataturtide acts in three pathways and activates the GIP, GLP-1 and glucagon receptors, it is likely to be an effective treatment for the following conditions:
- Type 2 Diabetes
- Obesity
- Fatty Liver Disease
- High Blood Pressure
Retatrutide: A New Triple Threat Against Weight Loss
Imagine a drug that fights fat by talking to three different messengers in your body at the same time. That's the idea behind Retatrutide, a new medication being tested for obesity. Retatrutide , new weight loss injection acts as a triple agonist peptide targeting the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R), results in reducing the hunger and increasing metabolism simultaneously. This retatrutide injection is still in developmental phase and as soon as it becomes available, you can buy online in Pharmacy planet for the lowest price in the UK as effective weight loss treatment for obesity and diabetes.
Potential for More effective weighloss
Most weight-loss medications target one specific hormone or messenger. Retatrutide is new weight-loss medication developed by Eli Lilly which acts like a triple agent, influencing three hormonal receptors (GLP-1, GIP, and glucagon) that play a role in feeling full, blood sugar control, and gut hormones. By targeting multiple pathways, Retatrutide might lead to more significant weight loss compared to some existing medications.Retatrutide has demonstrated an average weight loss of 24% in clinical trials.
What is the Average Weight Loss on Retatrutide Injection?
In Phase 2 trial , participants on retatrutide experienced significant weight loss results. Anyone with BMI of 35 or higher saw a mean weight reduction of 26.5% with the 8-mg dose and 26.4% with the 12-mg dose, compared to 21.3% and 21.5% respectively for those with a lower BMI. Women tended to have a higher mean weight loss than men across both dose groups (28.5% and 26.6% vs. 19.8% and 21.9%). Additionally, after 48 weeks, the trial showed an average weight loss of 24%, with some participants losing more than 30% of their body weight on the highest dose of 12 mg.
Still Under Development
It's important to remember that Retatrutide is in the early stages of testing (like a practice round for a new game). More research is needed to confirm its long-term safety and effectiveness before it becomes widely available.
Can I buy Retatrutide online in the UK?
No, it is not currently available in the UK as it is still undergoing clinical trials and regulatory reviews before it can be approved for prescription.
When will Retatrutide pen be available in Stock in the UK?
Retatrutide has not yet been approved or released for purchase in the UK. As it is currently in Phase III of testing, and it may take a few years before it becomes available on the market. Therefore, it is not yet accessible for treating conditions such as obesity and type 2 diabetes.
Alternative weight loss treatment :
As retatrutide is still under development, you can consider Wegovy , which is licensed for weight loss treatment in the UK
Retatrutide Benefits:
Retatrutide works by activating GIP, GLP-1 and glucagon receptors which controls hunger and lead to weight loss. In the longer term, prolonged use can be effective in the treatment and management of obesity. Retatrutide is believed to help improve insulin sensitivity in patients with type 2 diabetes and helping to control blood glucose levels.
Early indications suggest that Retatrutide also appears to support the preservation of lean muscle mass during weight loss. Patients treated with earlier generations of weight loss medicines have complained of losing muscle mass along with fat during the weight loss experience.
Maintaining lean muscle mass is vital for metabolic function and maintaining results after a period of weight loss. Retatrutide, along with other GLP1 receptor agonist are also believed to have anti-inflammatory properties which could be beneficial for those dealing with chronic inflammation, offering a potential path to relief. It is important to remember however that currently these drugs have not been licensed for this purpose.
Retatrutide is also thought to help reduce cholesterol levels which can reduce the risk of cardiovascular issues.
Retatrutide vs semaglutide
Retatrutide is still in the development and testing phase, but it is likely to enter the market as a treatment for obesity and/or type 2 diabetes. In future, it is likely that both retatrutide and semaglutide will be used for managing the obesity or type 2 diabetes.
Semaglutide and retatrutide belong to the same family of medicines, their mechanisms of action differ slightly. Semaglutide works by copying the action of the natural hormone GLP-1 which helps the body to produce more insulin and slows down the speed at which your stomach empties (gastric emptying). These actions help to control the levels of sugar circulating in the blood, reduce appetite and subsequently cause weight loss.
Retatrutide, on the other hand, still targets the GLP-1 hormone pathway. However, it also works on two other hormone receptors GIP and GCG. Targeting these additional pathways is believed to make retatrutide an even more effective options for weight loss and blood sugar control.
Semaglutide is already widlely available in the UK in the brands Wegovy and Ozempic. While everyone knows the name Ozempic as a wonder weight loss drug, it is only approved in the UK for the treatment on type 2 diabetes. Wegovy is the brand of semaglutide that has been approved for use in weight management. It is injected once weekly and can only be prescribed under the guidance of a licensed healthcare professional.
Retatrutide is still in the testing phase and undergoing clinical trials to establish its safety and efficacy. So, retatrutide is still likely to take some time before coming to market here in the UK. Nevertheless, it shows enormous promise as an extremely effective medicine for weight loss and blood sugar control. Retatrutide’s full range of benefits, side effects are not yet fully understood but it displays huge potential to be at the vanguard of the next generation of weight loss drugs.
What is the recommended dosage chart for retatrutide?
As yet, there are no comprehensive dosing guidelines regarding retatrutide. Generally, medicines in this class are started at the lowest dose and gradually increased. This helps to minimise side effects and allows the body to adjust to the medicine before stepping up to higher, more efficacious strengths.
So far, based on the the published results of clinical trials, patients have been prescribed a variety of doses between 1 and 12mg. Patients on higher doses tended to have a high propensity for weight loss over the trial period. However, these patients also showed a higher likelihood of experiencing side effects from retatrutide.
So, it is likely that retatrutide will have a graduated dosing regimen, whereby the dose is increased incrementally at the beginning of treatment in order to minimise the adverse effects of the medicine. However, the specifics of the drug’s doses and dosing schedule will only be fully known when retatrutide receives its product license in the UK.
What are the potential interactions of retatrutide with other medications?
Like all medicines, retatrutide has the potential to interact with other drugs. These interactions may cause other drugs to be less or more effective, or they could minimise the effectiveness of retatrutide itself. Currently, the exact list of drugs that retatrutide may interact with is unknown and is currently being researched.
As with any new medicine, it is important to talk to your clinician about any other medicines you are taking before starting to take retatrutide.
Can I get Retatrutide over the counter in the UK?
No. Retatrutide is likely to enter the UK market as a prescription medication requiring consultation with a healthcare professional prior to its prescription. The clinician will examine your health and treatment goals with you and determine if retatrutide is suitable for you.
Be the first to know
Sign up to be the first to know when Retrutide becomes available by clicking the 'Notify me once available' button above and enter your email.
We'll keep you up to date with the latest developments concerning Retatrutide and let you know as soon as it becomes available in the UK.
